ARTV vs CUBE · rev $251.0K vs P/E 25, rev $1.07B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ARTV revenue for 2024-12-31 was $251.0K. Net income was -$65.4M. Revenue was down 99.3% from 2023-12-31 to 2024-12-31. ARTV currently screens at market cap $37.3M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ARTV currently screens at market cap $37.3M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ARTV and CUBE stock pages for the full models.
Not investment advice.